PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.13%
EBIT growth above 1.5x TRVN's 8.28%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
37.34%
Operating income growth above 1.5x TRVN's 8.28%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
47.13%
Net income growth above 1.5x TRVN's 7.84%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
50.90%
EPS growth above 1.5x TRVN's 15.01%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
52.86%
Diluted EPS growth above 1.5x TRVN's 15.01%. David Dodd would see if there's a robust moat protecting these shareholder gains.
7.67%
Share count expansion well above TRVN's 8.34%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
12.32%
Diluted share count expanding well above TRVN's 8.34%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
33.57%
Positive OCF growth while TRVN is negative. John Neff would see this as a clear operational advantage vs. the competitor.
33.08%
Positive FCF growth while TRVN is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9761.92%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-7404.36%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-3986.05%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-11268.60%
Negative 10Y net income/share CAGR while TRVN is at 18.95%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-11424.82%
Negative 5Y net income/share CAGR while TRVN is 18.95%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
97.34%
3Y net income/share CAGR above 1.5x TRVN's 18.95%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
No Data
No Data available this quarter, please select a different quarter.
7616.79%
Equity/share CAGR of 7616.79% while TRVN is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
547.30%
Equity/share CAGR of 547.30% while TRVN is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.86%
Negative asset growth while TRVN invests at 58.05%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-8.66%
We have a declining book value while TRVN shows 57.10%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-100.00%
We’re deleveraging while TRVN stands at 1.61%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-26.31%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-49.44%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.